首页> EClinicalMedicine> First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with <i>de novo</i> coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT.

First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with <i>de novo</i> coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT.

导出 LinkOut

翻译打印收藏纠错

第一作者： Shigeru,Saito

第一单位： Heart Center, Iryohojin Tokushukai Shonan Kamakura General Hospital, Kamakura City, Japan.

作者： Shigeru,Saito ^[1] ; Johan,Bennett ^[2] ; Holger M,Nef ^[3] ; Mark,Webster ^[4] ; Atsuo,Namiki ^[5] ; Akihiko,Takahashi ^[6] ; Tsunekazu,Kakuta ^[7] ; Seiji,Yamazaki ^[8] ; Yoshisato,Shibata ^[9] ; Douglas,Scott ^[10] ; Mathias,Vrolix ^[11] ; Madhav,Menon ^[12] ; Helge,Möllmann ^[13] ; Nikos,Werner ^[14] ; Antoinette,Neylon ^[15] ; Zlatko,Mehmedbegovic ^[15] ; Pieter C,Smits ^[15] ; Marie-Claude,Morice ^[15] ; Stefan,Verheye ^[16] ; BIOADAPTOR-RCT Collaborators

作者单位： Heart Center, Iryohojin Tokushukai Shonan Kamakura General Hospital, Kamakura City, Japan. ^[1] Department of Cardiovascular Medicine, UZ Leuven, Leuven, Belgium. ^[2] Department of Cardiology and Angiology, University of Giessen, Giessen, Germany. ^[3] Cardiac Investigation Unit, Auckland City Hospital, Auckland, New Zealand. ^[4] Department of Cardiology, Kanto Rosai Hospital, Nakahara-ku, Kawasaki-shi, Japan. ^[5] Department of Cardiology, Takahashi Hospital, Kobe City, Japan. ^[6] Cardiovascular Medicine, Tsuchiura Kyodo Hospital, Tsuchiura City, Japan. ^[7] Department of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan. ^[8] Department of Cardiology, Miyazaki Medical Association Hospital, Miyazaki City, Japan. ^[9] Department of Cardiology, Middlemore Hospital, Auckland, New Zealand. ^[10] Department of Cardiology, Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium. ^[11] Department of Cardiology, Waikato Hospital, Hamilton, New Zealand. ^[12] Department of Cardiology, St. Johannes Hospital Dortmund, Dortmund, Germany. ^[13] Department of Cardiology, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany. ^[14] CERC (Cardiovascular European Research Center) ICPS Ramsay, Massy, France. ^[15] Interventional Cardiology, ZNA Cardiovascular Center Middelheim, Antwerp, Belgium. ^[16]

关键词 Bioadaptor Coronary artery disease Cyclic pulsatility Drug-eluting stents Percutaneous coronary intervention Vessel function

DOI 10.1016/j.eclinm.2023.102304

PMID 38106564

发布时间 2024-10-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

EClinicalMedicine

2023年65卷

102304页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

EClinicalMedicine

2023年65卷

102304页

检索历史清除

First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with <i>de novo</i> coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT.

EClinicalMedicine

相似文献

同项目论文

EClinicalMedicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with <i>de novo</i> coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT.

EClinicalMedicine

相似文献

同项目论文

EClinicalMedicine

相关期刊

检索历史清除